Menu Investors Press Releases Overview Press Releases Events + Presentations Company Information Stock Information Analyst Coverage SEC Filings Corporate Governance News Alerts Recent Press Releases Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 12, 2021 Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event November 11, 2021 Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference November 10, 2021 Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting November 1, 2021 Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements October 12, 2021 Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board September 14, 2021 Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit August 11, 2021 Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update August 10, 2021 Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR July 13, 2021 Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update May 13, 2021 Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer May 11, 2021 Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit May 7, 2021 Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum April 26, 2021 Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval April 13, 2021 Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update March 29, 2021 Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference March 3, 2021 Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors February 23, 2021 Vallon Pharmaceuticals Announces Closing of Initial Public Offering February 12, 2021 Vallon Pharmaceuticals Announces Pricing of Initial Public Offering February 9, 2021 Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting January 19, 2021 Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting January 8, 2021 Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR November 9, 2020 Vallon Newsroom Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.